The acute myeloid leukemia (AML) treatment landscape has changed substantially since 2017. New targeted drugs have emerged, including venetoclax to target B-cell lymphoma 2, midostaurin and gilteritinib to target FLT3, and ivosidenib and enasidenib to target mutant isocitrate dehydrogenase 1 and 2...
Acute myeloid leukemia (AML) also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia is a cancer that starts in the bone marrow (the soft inner part of certain bones, where new blood cells are made), moving often into...
A novel assay that detects a unique molecular marker in patients with acute myeloid leukemia (AML) may revolutionize the way this disease is detected and treated according to a new report recently published inThe Journal of Molecular Diagnosticspublished by Elsevier. This assay may improve the detect...
Larson ML, Venugopal P. Clofarabine: a new treatment option for patients with acute myeloid leukemia. Expert Opin Pharmacother. 2009;10(8):1353-7.Larson ML, Venugopal P. Clofarabine: a new treatment option for patients with acute myeloid leukemia. Expert Opin Pharmacother. 2009; 10 (8): ...
Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow It occurs when the bone marrow, which is responsible for producing blood cells, starts making too many abnormal white blood cells called myeloblasts.
Acute myeloid leukemia (AML) is a type of blood cancer.Learn about this cancer that forms in the bone and bone marrow. Treatments include medications and bone marrow transplant.
Cancer vaccines are promising treatments to prevent relapse after chemotherapy in acute myeloid leukemia (AML) patients, particularly for those who cannot tolerate intensive consolidation therapies. Here, we report the development of an AML cell membrane-coated nanoparticle (AMCNP) vaccine platform, in ...
This 45-page report provides a behind-the-scenes look at the treatment experience for those living with acute myeloid leukemia (AML). Using detailed quantitative data, it gives a full picture of the AML treatment story - from HCP conversations to tr...
Geoffrey Uy, MD, assistant professor of medicine, Division of Oncology, Section of Bone Marrow Transplantation, Washington University School of Medicine, Siteman Cancer Center, discusses therapy selection in acute myeloid leukemia (AML). It is becoming increasingly complex to select the appropriate ...
The BCL-2 inhibitor Venetoclax is a promising agent for the treatment of acute myeloid leukemia (AML). However, many patients are refractory to Venetoclax, and resistance develops quickly. ATP-binding cassette (ABC) transporters mediate chemotherapy resistance but their role in modulating the activity...